



PHARMA PRESCRIBED .COM

NEWSLETTER · IN CONVERSATION WITH MATTHEW MACE

Faster trials, smarter collaboration

Matthew Mace — founder of Study Connect and a cardiac-innovation leader — on speeding up trials, the FDA-breakthrough device he helped bring to market, and turning bold ideas into patient impact.

Matthew Mace wears several hats: founder of Study Connect, host of the Study Success podcast, and a newly appointed board director at Precision Cardiovascular. Previously, as a co-founder and CSO, he led what he describes as the largest hemodynamic study in heart-failure history — securing an FDA breakthrough device designation and raising over \$10 million. Fifteen years across cardiology, AI and MedTech have given him an unusually practical view of turning vision into impact.



Faster trials, smarter collaboration — all of it for the benefit of patients.

— Matthew Mace, on Pharma Prescribed

Speed as a moral issue

Study Connect exists to streamline scientific innovation through faster trials and smarter collaboration. For Matt this isn't efficiency for its own sake — in

cardiology, where he's spent his career, the time between an idea and a patient is measured in lives.

Proof he's done it

The credibility comes from having actually shipped hard things — a record-scale heart-failure study, an FDA breakthrough designation, real money raised, and a novel technology brought to market. He talks about collaboration because he's seen first-hand what its absence costs.

Amplifying the field

Through his podcast and board work he's as interested in lifting the whole industry's game as his own — amplifying bold ideas and practical strategies. It's a builder's instinct pointed outward as well as in.



Listen to the full episode

Matthew Mace on Pharma Prescribed — at pharmaprescribed.com and wherever you get your podcasts.

Matthew Mace *is the founder of Study Connect, host of the Study Success podcast and a board director at Precision Cardiovascular.*